ABVX:EPA
Abivax SA
€79.55
arrow_upward
+0.38%(+0.30) 1D
Nov 4, 5:38:16 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€79.60
High
€80.85
Low
€78.15
Mkt. cap
7.31B
Avg. vol.
112.48K
Volume
87.75K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€79.60
High
€80.85
Low
€78.15
Mkt. cap
7.31B
Avg. vol.
112.48K
Volume
87.75K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
Yahoo Finance
·
41 minutes ago
Dow, S&P 500, Nasdaq Futures Mixed After A Democratic Sweep In Midterms: NVDA, MU, SNDK, NBIS, IREN In Focus
www.marketscreener.com
·
16 minutes ago
Backblaze Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mitrade
·
36 minutes ago
S&P 500 Flashes a Signal Never Seen in 36 Years. What’s Next?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Industry-
Websiteabivax.com